BAG3 is a co-chaperone and adapter protein that bridges different classes of molecular chaperones, including heat shock proteins 70 (HSP70s) and small heat shock proteins such as HSPB8. It functions as a nucleotide-exchange factor that promotes ADP release from HSP70s, facilitating client protein turnover and release. BAG3 also exhibits anti-apoptotic activity and regulates heat shock factor 1 (HSF1) nucleocytoplasmic transport, supporting broader cellular stress responses. Pathogenic BAG3 variants cause myofibrillar myopathy, characterized by Z-disk disintegration and myofibrillar degradation; affected individuals may present with rapidly progressive and severe phenotypes 1. BAG3 loss of function is associated with dilated cardiomyopathy through multiple mechanisms: it regulates sarcomere protein turnover in cardiomyocytes and, in cardiac fibroblasts, controls transforming growth factor-β receptor 2 (TGFBR2) signaling and mitophagy 23. Notably, the common C151R variant acts as a bidirectional modifier, reducing dilated cardiomyopathy risk while increasing hypertrophic cardiomyopathy risk 4. Recent evidence implicates BAG3 in neurodegeneration: astrocyte BAG3 enhances clearance of alpha-synuclein and tau through autophagy 5, and neuronal BAG3 attenuates tau hyperphosphorylation and cognitive deficits after traumatic brain injury 6. BAG3 is also elevated in multiple cancer types and correlates with tumor progression, suggesting therapeutic potential through BAG3-targeting approaches such as USP26 inhibition 78.